Association of adenylate cyclase-associated protein 1 with coronary artery disease
Samo za registrovane korisnike
2017
Autori
Munjas, JelenaSopić, Miron
Spasojević-Kalimanovska, Vesna
Kalimanovska-Oštrić, Dimitra
Andelković, Kristina
Jelić-Ivanović, Zorana
Članak u časopisu (Objavljena verzija)
Metapodaci
Prikaz svih podataka o dokumentuApstrakt
BackgroundAdenylate cyclase-associated protein 1 (CAP1) is a recently identified receptor for human resistin. As resistin has been related to CAD development and progression and CAP1 has never been evaluated in CAD, the aim of this study was to determine its peripheral blood mononuclear cells (PBMCs) mRNA in patients with CAD, and resistin plasma concentration, PBMCs resistin and CD36 mRNA, considering resistis ability to stimulate CD36 expression invitro. Materials and methodsThis case-controlled study included 27 healthy subjects (CG) and 66 patients requiring coronary angiography. Of the latter, 42 had nonsignificant CAD whereas 24 had significant CAD. Circulating resistin was measured by ELISA; PBMCs CAP1, resistin and CD36 mRNA were determined by real-time PCR. ResultsPatients with significant as well as patients with nonsignificant CAD had significantly higher resistin concentrations compared to the CG (P lt 0 lt bold> lt /bold>001; P=0 lt bold> lt /bold>003). Resistin mRNA did n...ot show significant difference between the investigated groups. CAP1 and CD36 mRNA were significantly higher in significant CAD (P lt 0 lt bold> lt /bold>001; P lt 0 lt bold> lt /bold>001, respectively) and nonsignificant CAD (P lt 0 lt bold> lt /bold>001; P lt 0 lt bold> lt /bold>001, respectively) compared to the CG; significant CAD showed significantly higher CD36 mRNA (P=0 lt bold> lt /bold>040) compared to the nonsignificant CAD group. Multiple linear regression analysis identified Tg and CD36 mRNA as independent predictors of CAP1 (R-2=0 lt bold> lt /bold>402; adjR(2)=0 lt bold> lt /bold>376). ConclusionSignificant up-regulation of PBMCs CAP1, CD36 mRNA and plasma resistin found in significant CAD, as well as in nonsignificant CAD compared to CG, indicates that resistin could be able to exert its effects stronger on cells with up-regulated CAP1 mRNA thus contributing atherosclerosis development.
Ključne reči:
CAP1 / CD36 / coronary artery disease / resistinIzvor:
European Journal of Clinical Investigation, 2017, 47, 9, 659-666Izdavač:
- Wiley, Hoboken
Finansiranje / projekti:
DOI: 10.1111/eci.12787
ISSN: 0014-2972
PubMed: 28707728
WoS: 000408480300006
Scopus: 2-s2.0-85028307603
Institucija/grupa
PharmacyTY - JOUR AU - Munjas, Jelena AU - Sopić, Miron AU - Spasojević-Kalimanovska, Vesna AU - Kalimanovska-Oštrić, Dimitra AU - Andelković, Kristina AU - Jelić-Ivanović, Zorana PY - 2017 UR - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2817 AB - BackgroundAdenylate cyclase-associated protein 1 (CAP1) is a recently identified receptor for human resistin. As resistin has been related to CAD development and progression and CAP1 has never been evaluated in CAD, the aim of this study was to determine its peripheral blood mononuclear cells (PBMCs) mRNA in patients with CAD, and resistin plasma concentration, PBMCs resistin and CD36 mRNA, considering resistis ability to stimulate CD36 expression invitro. Materials and methodsThis case-controlled study included 27 healthy subjects (CG) and 66 patients requiring coronary angiography. Of the latter, 42 had nonsignificant CAD whereas 24 had significant CAD. Circulating resistin was measured by ELISA; PBMCs CAP1, resistin and CD36 mRNA were determined by real-time PCR. ResultsPatients with significant as well as patients with nonsignificant CAD had significantly higher resistin concentrations compared to the CG (P lt 0 lt bold> lt /bold>001; P=0 lt bold> lt /bold>003). Resistin mRNA did not show significant difference between the investigated groups. CAP1 and CD36 mRNA were significantly higher in significant CAD (P lt 0 lt bold> lt /bold>001; P lt 0 lt bold> lt /bold>001, respectively) and nonsignificant CAD (P lt 0 lt bold> lt /bold>001; P lt 0 lt bold> lt /bold>001, respectively) compared to the CG; significant CAD showed significantly higher CD36 mRNA (P=0 lt bold> lt /bold>040) compared to the nonsignificant CAD group. Multiple linear regression analysis identified Tg and CD36 mRNA as independent predictors of CAP1 (R-2=0 lt bold> lt /bold>402; adjR(2)=0 lt bold> lt /bold>376). ConclusionSignificant up-regulation of PBMCs CAP1, CD36 mRNA and plasma resistin found in significant CAD, as well as in nonsignificant CAD compared to CG, indicates that resistin could be able to exert its effects stronger on cells with up-regulated CAP1 mRNA thus contributing atherosclerosis development. PB - Wiley, Hoboken T2 - European Journal of Clinical Investigation T1 - Association of adenylate cyclase-associated protein 1 with coronary artery disease VL - 47 IS - 9 SP - 659 EP - 666 DO - 10.1111/eci.12787 ER -
@article{ author = "Munjas, Jelena and Sopić, Miron and Spasojević-Kalimanovska, Vesna and Kalimanovska-Oštrić, Dimitra and Andelković, Kristina and Jelić-Ivanović, Zorana", year = "2017", abstract = "BackgroundAdenylate cyclase-associated protein 1 (CAP1) is a recently identified receptor for human resistin. As resistin has been related to CAD development and progression and CAP1 has never been evaluated in CAD, the aim of this study was to determine its peripheral blood mononuclear cells (PBMCs) mRNA in patients with CAD, and resistin plasma concentration, PBMCs resistin and CD36 mRNA, considering resistis ability to stimulate CD36 expression invitro. Materials and methodsThis case-controlled study included 27 healthy subjects (CG) and 66 patients requiring coronary angiography. Of the latter, 42 had nonsignificant CAD whereas 24 had significant CAD. Circulating resistin was measured by ELISA; PBMCs CAP1, resistin and CD36 mRNA were determined by real-time PCR. ResultsPatients with significant as well as patients with nonsignificant CAD had significantly higher resistin concentrations compared to the CG (P lt 0 lt bold> lt /bold>001; P=0 lt bold> lt /bold>003). Resistin mRNA did not show significant difference between the investigated groups. CAP1 and CD36 mRNA were significantly higher in significant CAD (P lt 0 lt bold> lt /bold>001; P lt 0 lt bold> lt /bold>001, respectively) and nonsignificant CAD (P lt 0 lt bold> lt /bold>001; P lt 0 lt bold> lt /bold>001, respectively) compared to the CG; significant CAD showed significantly higher CD36 mRNA (P=0 lt bold> lt /bold>040) compared to the nonsignificant CAD group. Multiple linear regression analysis identified Tg and CD36 mRNA as independent predictors of CAP1 (R-2=0 lt bold> lt /bold>402; adjR(2)=0 lt bold> lt /bold>376). ConclusionSignificant up-regulation of PBMCs CAP1, CD36 mRNA and plasma resistin found in significant CAD, as well as in nonsignificant CAD compared to CG, indicates that resistin could be able to exert its effects stronger on cells with up-regulated CAP1 mRNA thus contributing atherosclerosis development.", publisher = "Wiley, Hoboken", journal = "European Journal of Clinical Investigation", title = "Association of adenylate cyclase-associated protein 1 with coronary artery disease", volume = "47", number = "9", pages = "659-666", doi = "10.1111/eci.12787" }
Munjas, J., Sopić, M., Spasojević-Kalimanovska, V., Kalimanovska-Oštrić, D., Andelković, K.,& Jelić-Ivanović, Z.. (2017). Association of adenylate cyclase-associated protein 1 with coronary artery disease. in European Journal of Clinical Investigation Wiley, Hoboken., 47(9), 659-666. https://doi.org/10.1111/eci.12787
Munjas J, Sopić M, Spasojević-Kalimanovska V, Kalimanovska-Oštrić D, Andelković K, Jelić-Ivanović Z. Association of adenylate cyclase-associated protein 1 with coronary artery disease. in European Journal of Clinical Investigation. 2017;47(9):659-666. doi:10.1111/eci.12787 .
Munjas, Jelena, Sopić, Miron, Spasojević-Kalimanovska, Vesna, Kalimanovska-Oštrić, Dimitra, Andelković, Kristina, Jelić-Ivanović, Zorana, "Association of adenylate cyclase-associated protein 1 with coronary artery disease" in European Journal of Clinical Investigation, 47, no. 9 (2017):659-666, https://doi.org/10.1111/eci.12787 . .